1. Introduction
===============

Glomerulonephritis is a major determinant of the course and prognosis of SLE and is evident in 40%--85% of patients ([@b1-epj-07-1680]). Raised titers of anti-DNA and hypocomplementemia have been reported to be associated with activity of the disease ([@b2-epj-07-1680]). However, their non-specificity led to the search for other antibodies that might contribute to nephritis and help diagnose renal flare ([@b3-epj-07-1680]). IL10, a cytokine produced by monocytes and to a lesser extent lymphocytes, has pleiotropic effects in immune regulation and inflammation ([@b4-epj-07-1680]). It enhances B cell survival, proliferation, differentiation, and antibody production, and these effects play a role in autoimmune diseases ([@b5-epj-07-1680]). A 40-fold increase in risk for developing SLE was identified in individuals with particular alleles of both IL10 and bcl2 genes ([@b6-epj-07-1680]), and it has been considered that polymorphisms of IL10 contribute---at least in part---to the genetics involved in SLE. Among identified polymorphisms in the IL10 promoter, three linked single nucleotid polymorphisms (SNPs) of −1082 G/A, 819 T/C, and −592 A/C have been shown to influence the IL10 gene expression ([@b7-epj-07-1680]). Compared with the −592 C allele, the 592 A is associated with lower IL10 production in vitro ([@b8-epj-07-1680]). This study investigated the −592 A/C polymorphism in patients with and without lupus nephritis and assessed its influence on IL10 secretion in vivo and its role in pathogenesis and clinicopathological characteristics of lupus nephritis.

2. Material and Methods
=======================

Forty SLE patients (34 females and 6 males) were recruited in the study from those attending the nephrology department of the Theodor Bilharz Research Institute (outpatient clinic and inpatient ward) in 2013. Written consent was acquired from all participants after explaining the details, benefits, and risks to them. Patients were divided into two groups according to clinical presentations and laboratory investigations. Group I comprised 15 SLE patients (13 females and 2 males) without evidence of nephritis. Group II comprised 25 SLE patients (21 females and 4 males) diagnosed with lupus nephritis according to American College of Rheumatology (ACR) criteria (i.e., proteinuria \> 500 mg/day and/or red cell casts). The diagnosis of renal involvement was confirmed by renal biopsy.

The biopsies were classified according to the International Society of Nephrology/Renal Pathology Society. Classes III and IV are considered more active while classes I, II, and IV are considered less active. Exclusion criteria were: SLE patients with proteinuria other than lupus nephritis, such as pregnancy and fever, and/or patients with renal impairment due to any other cause than lupus nephritis, such as diabetic nephropathy. In addition, patients with HCV, HBV, and other connective tissue diseases other than SLE were excluded from the study.

All patients were subjected to the following: (1) complete history and physical examination; (2) routine laboratory investigations, including complete blood count, erythrocyte sedimentation rate, serum urea, serum creatinine, C-reactive protein, creatinine clearance, urine analysis, and 24-hour protein excretion; 3) immunological profiles, including antinuclear antibody (ANA) by indirect immune-fluorescence principle, Anti-ds DNA by solid phase immunoassays, and complement level (C3 and C4) by using BN ProSpee nephelometery; and 4) serum level of IL10 by indirect solid phase enzyme immunoassay (ELISA).

Results were expressed as means ± standard deviation (SD) of the means or number (%). Different parameters in the two studied groups were compared using an unpaired t-test. Parameters in different pathological classes were compared using ANOVA. Categorical data were compared using a Chi square test. The correlation between different parameters in the cases group was defined using the Pearson product--moment correlation coefficient. The data were considered significant if the p-value was equal to or less than 0.05 and highly significant if the p-value \< 0.01. Statistical analyses were performed with the aid of the SPSS computer program (version 12, Windows).

3. Results
==========

Forty systemic lupus erythromatosis patients from the nephrology department of TBRI were included in the present study (34 females and 6 males). They were classified into two groups: 15 without nephritis and 25 with evidence of lupus nephritis (8 patients has class III, 11 patients has class IV, and 6 patients has class V nephritis). All patients were analyzed for the presence of the 592 A/C polymorphism. The demographic, clinical and laboratory data are summarized in [Tables 1](#t1-epj-07-1680){ref-type="table"}, [2](#t2-epj-07-1680){ref-type="table"}, and [3](#t3-epj-07-1680){ref-type="table"}. As shown in [Table 3](#t3-epj-07-1680){ref-type="table"}, a significant difference existed between group I and II in terms of creatinine, BUN, urea, creatinine clearance, protein in urine/24 hours, C3, C4, and anti-dsDNA. In addition, the mean values of IL10 in the two groups studied were 5.11 ± 7.58 and 14.66 ± 39.14, and no statistically significant difference emerged between group I and II in terms of IL10 (p = 0.358). [Table 4](#t4-epj-07-1680){ref-type="table"} shows the correlation analysis between IL10 and the different parameters studied in group II according to the Pearson product--moment correlation coefficient. [Tables 5](#t5-epj-07-1680){ref-type="table"} and [6](#t6-epj-07-1680){ref-type="table"} present the genotype frequency and alleles' frequency in the two groups studied. [Table 7](#t7-epj-07-1680){ref-type="table"} shows the comparison between mean values of IL10, Creatinine clearance and 24-hour protein measured before and after treatment in group II. Finally, [Table 8](#t8-epj-07-1680){ref-type="table"} summarizes the results of the comparison between mean values of IL10 measured before and after treatment in the cases group (group I).

4. Discussion
=============

SLE is a systemic autoimmune disease characterized by autoantibodies, B cell hyperactivity, and immune complex formation ([@b9-epj-07-1680]). Glomerulonephritis is a frequent and often severe feature and is one of the major determinants of poor outcomes. Therefore, reliable markers for diagnosing and monitoring lupus nephritis are critically important. IL10 enhances B cell survival, proliferation, and antibody production, and these effects appear to play a role in autoimmune diseases ([@b10-epj-07-1680]). High IL10 expression and the corresponding IL10 alleles have been suggested to play a causal role in SLE ([@b11-epj-07-1680]), and polymorphisms of IL10 contribute---at least in part---to the genetics involved in SLE ([@b12-epj-07-1680]). Genetics could account for up to 75% of the IL10 production ([@b13-epj-07-1680]). The promoter of the IL10 gene has been shown to be highly polymorphic. Studies seeking to find an association between IL10 promoter polymorphisms and SLE have yielded varying results among different populations ([@b14-epj-07-1680]). For the most frequently studied 1082/-819/-592 SNPs, no association with SLE incidence has been found in Chinese, Dutch, or British populations ([@b15-epj-07-1680]), and no statistical difference has been found in the distribution of IL10-592 genotypes between lupus nephritis patients and those without renal involvement, suggesting that the −592 polymorphism in the IL10 gene may not be associated with lupus nephritis susceptibility.

Our study showed an increase in serum IL10 in lupus nephritis patients compared to those without renal involvement (without statistical significance), which concurs with the finding of Lit et al. ([@b16-epj-07-1680]). This proves the importance of IL10 in the pathogenesis of lupus nephritis. In addition, no statistically significant difference emerged in the level of serum IL10 among different pathological classes of our study or between active and chronic cases (which might be due to the small sample size). No statistically significant difference was found in the distribution of AC and CC genotypes between those with renal involvement and without. The CC genotype was more frequent in active cases with no statistical significance. In addition, no significant difference occurred in SLEDAI, anti DNA, proteinuria, hematuria, or casts in the different genotypes, which is contrary to Zhuet et al.'s ([@b17-epj-07-1680]) finding that patients with class IV had a higher frequency of AC/CC genotypes than those with class V lupus nephritis (genetic factor) contributing to the glomerular lesions in patients with lupus nephritis. Regarding the influence of IL10-592 A/C polymorphism on serum IL10 levels in lupus nephritis patients, no evidence of genetic regulation was reported in our study; however, its effect on renal lesions may affect the local IL10 levels in the glomeruli, not in the serum IL10, or perhaps be linked with some other genes that play a role in the pathological lesions of glomeruli. Anti DNA antibodies may play a role; however, our results show a negative correlation between their level and renal cases.

5. Conclusions
==============

In conclusion, the findings of this study showed that IL10 gene −592 A/C polymorphism, although not associated with lupus nephritis susceptibility, does have an impact.
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###### 

Comparison of demographic data in two groups studied

  Demographic variables        Group *I* (n=15)     Group II (n=25)   p-value
  ---------------------------- -------------------- ----------------- ---------
  Age                          29.4 ± 7.02          27.68 ± 7.03      0.458
  Gender (F/M)                 13/2 (86.7%/13.3%)   21/4 (84%/16%)    0.819
  Duration of disease (yrs.)   1.55 ± 1.13          2.20 ± 1.59       0.168

Data are expressed as mean ± SD or a number (%)

###### 

Comparison of clinical manifestations in two groups studied

  Variables                       Group *I* (n=15)   Group *II* (n=25)   p-value    
  ------------------------------- ------------------ ------------------- ---------- -------
  Dermatological manifestations   Malar rash         15 (100%)           12 (48%)   0.003
  Discoid rash                    0 (0%)             1 (4%)              0.433      
  Photosensitivity                11 (73.3%)         19 (76%)            0.850      
  Hair fall                       14 (93.3%)         15 (60%)            0.022      
  Oral ulcer                      8 (53.3%)          15 (60%)            0.680      
  Articular manifestations        Arthralgia         13 (86.7%)          16 (64%)   0.120
  Fever/malaise                   8 (53.3%)          7 (28%)             0.109      
  Seizure                         2 (13.3%)          2 (8%)              0.586      
  Psychosis                       0 (0%)             0 (0%)              \-\--      
  Serositis (pleural effusion)    0 (0%)             7 (17.5%)           0.163      

Data are expressed as a number (%)

###### 

Comparison of laboratory manifestations in two groups studied

  Variables                    Group *I* (n=15)   Group II (n=25)     p-value        
  ---------------------------- ------------------ ------------------- -------------- -------
  Complete blood count (CBC)   Hb (g/dL)          10.61 ± 1.02        10.31 ± 1.62   0.516
  RBCs (×10^6^/μL)             3.87 ± 0.53        4.06 ± 0.39         0.203          
  WBCs (10^9^/L)               7.09 ± 3.93        6.21 ± 2.09         0.361          
  Platelet count (10^9^/L)     243.87 ± 45.81     206.96 ± 70.44      0.079          
  S. creatinine                0.58 ± 0.12        1.76 ± 1.63         0.001          
  BUN                          11.77 ± 2.94       39.88 ± 38.80       0.001          
  Urea                         27.33 ± 7.11       67.32 ± 68.99       0.008          
  Protein 24 hrs.              121.33 ± 23.29     2587.00 ± 2439.50   0.001          
  Creatinine clearance         107.07 ± 7.46      67.80 ± 28.66       0.001          
  CRP                          6.63 ± 5.31        6.92 ± 6.06         0.876          
  ESR                          67.27 ± 39.00      88.08 ± 27.80       0.056          
  C3                           1.13 ± 0.17        0.63 ± 0.49         0.001          
  C4                           0.74 ± 0.61        0.26 ± 0.42         0.012          
  Anti-dsDNA                   59.19 ± 23.96      169.71 ± 162.47     0.003          

Data are expressed as mean ± SD

###### 

Correlation between IL10 and different parameters studied in group II

  Variables              Pearson product--moment correlation coefficient   Sig. (2-tailed)
  ---------------------- ------------------------------------------------- -----------------
  Urea                   −0.179                                            0.392
  BUN                    −0.159                                            0.448
  Serum creatinine       −0.169                                            0.421
  ESR                    −0.072                                            0.734
  Creatinine Clearance   −0.001                                            0.996
  24hr.pro               −0.214                                            0.305
  C3                     −0.358                                            0.079
  C4                     0.401                                             0.047
  Anti-dsDNA             −0.09                                             0.67

###### 

Genotype frequency in the two groups studied

  Genotype     Group *I* (n=15)   Group II (n=25)   p-value
  ------------ ------------------ ----------------- ---------
  AA (n= 2)    0 (0%)             2 (8%)            
  AC (n= 20)   7 (46.7%)          13 (52%)          0.444
  CC (n= 18)   8 (53.3%)          10 (40%)          

Data are expressed as a number (%).

###### 

Alleles' frequency in the two groups studied

  Alleles     Group *I* (n=15)   Group II (n=25)   p-value
  ----------- ------------------ ----------------- ------------
  A (n= 24)   7 (23.3%)          17 (34%)          0.313 (NS)
  C (n= 79)   23 (76.7%)         33 (66%)          

Data are expressed as a number (%).

###### 

Comparison of mean values of IL10, creatinine clearance, and 24-hour protein measured before and after treatment in group II

  Variables                 Before (n= 25)      After (n= 25)       p-value
  ------------------------- ------------------- ------------------- ---------
  Serum IL10 (U/ml)         15.24 ± 39.87       3.78 ± 4.05         0.165
  Cr. Clearance (m/min.)    68.05 ± 24.28       67.80 ± 28.66       0.947
  Protein 24 hrs (mg/day)   2587.24 ± 2439.54   1735.96 ± 1595.03   0.015

Data are expressed as mean ± SD.

###### 

Comparison of mean values of IL10 measured before and after treatment in cases group (group *I*)

  Variables                            Active (n= 14)   Chronic (n= 6)   p-value
  ------------------------------------ ---------------- ---------------- ------------
  Serum IL10 before treatment (U/ml)   9.41 ± 13.60     4.73 ± 5.33      0.431 (NS)
  Serum IL10 after treatment (U/ml)    3.56 ± 4.44      2.78 ± 2.75      0.700 (NS)

Data are expressed as mean ± SD.
